Literature DB >> 22226330

Effects of domperidone on QTc interval in infants.

M C Vieira1, N I Miyague, K Van Steen, S Salvatore, Y Vandenplas.   

Abstract

AIM: To prospectively evaluate the effects of oral domperidone on the QTc interval in infants.
METHODS: Infants (0-1 year) with a diagnosis of gastro-oesophageal reflux (GOR) disease were included. A 12-lead electrocardiography (ECG) was performed in all infants at baseline and 1 h after the intake of domperidone after 7-14 days; the corrected QTc interval was calculated by one investigator (MV) according to Bazett's formula.
RESULTS: Forty-five infants were enrolled in this study. The mean gestational age was of 38.6 weeks (35.5-42.0), and the mean age at the start of domperidone was 75.3 days (19-218 days). No statistically significant difference in corrected QTc was observed between baseline and the second ECG (0.389 ± 0.02 vs. 0.397 ± 0.31; p 0.130)). A trend was observed regarding gender: Although there was no difference in QTc change in girls (p 0.622), there was a strong trend in boys (p 0.051). Two infants (both boys) had a clinically significant QTc prolongation (> 460 msec) without symptoms. The Spearman correlation test showed no relation between the QTc change and age (r: -0.05822; p 0.7284). There was no relation between domperidone dosage and QTc change.
CONCLUSION: Overall, the group-analysis showed no statistical significant difference in QTc duration induced by domperidone. However, 2/45 (4.4%) infants had a prolonged QTc interval (> 460 msec) induced by domperidone. As a consequence, QTc measurement should be recommended in routine in infants when domperidone is started.
© 2012 The Author(s)/Acta Paediatrica © 2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226330     DOI: 10.1111/j.1651-2227.2012.02593.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

Review 1.  Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature.

Authors:  Amy D Morris; Jennifer Chen; Elaine Lau; Jennifer Poh
Journal:  Can J Hosp Pharm       Date:  2016-06-30

2.  Drug-Induced QT Interval Prolongation in Children: Are the Kids Alright?

Authors:  James E Tisdale
Journal:  Can J Hosp Pharm       Date:  2016-06-30

3.  [Not Available].

Authors:  James E Tisdale
Journal:  Can J Hosp Pharm       Date:  2016-06-30

Review 4.  Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.

Authors:  Shlomi Cohen; Mirjam Bueno de Mesquita; Francis B Mimouni
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

5.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

6.  [Knowledge and practice of Brazilian pediatricians concerning gastroesophageal reflux disease in infants].

Authors:  Ana Cristina Fontenele Soares; Carla Lima de Freitas; Mauro Batista de Morais
Journal:  Rev Paul Pediatr       Date:  2015-02-07

7.  Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe.

Authors:  Daniel Fife; John Waller; Sigal Kaplan; Peter Hu; Syd Phillips; Susan A Oliveria; Ute Richarz
Journal:  Clin Drug Investig       Date:  2019-11       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.